HDAC9 and familial pancreatic carcinoma: Recent studies in the literature demonstrate that JQ1 in combination with the PARP inhibitor olaparib, the immunotherapeutic agent α-PD-L1, the HDAC inhibitor SAHA, or arsenic trioxide are more effective than these drugs as single agents in in vivo models of pancreatic cancer [17,28,30,31].